Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer

Paul A. Bunn, F. Anthony Greco, Lawrence Einhorn

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

The discovery that etopside is one of the most active drugs in small-cell lung cancer (SCLC) led to its incorporation into a number of first-line combination chemotherapy regimens. The cyclophosphamide/ doxorubicin/etoposide (CAE) regimen was shown to be as active or more active than other standard regimens in nonrandomized studies. In a randomized study presented in this report, the CAE regimen was significantly superior to the cyclophosphamide/doxorubicin/vincristine (CAV) regimen for response duration and survival in extensive-stage patients. In limited-stage patients the results were slightly better with CAE. In addition, CAE lacked the neurotoxicity of CAV.

Original languageEnglish
Pages (from-to)45-53
Number of pages9
JournalSeminars in Oncology
Volume13
Issue number3 SUPPL. 3
StatePublished - 1986

Fingerprint

Small Cell Lung Carcinoma
Etoposide
Doxorubicin
Cyclophosphamide
Vincristine
Therapeutics
Combination Drug Therapy
Survival
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology

Cite this

Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer. / Bunn, Paul A.; Greco, F. Anthony; Einhorn, Lawrence.

In: Seminars in Oncology, Vol. 13, No. 3 SUPPL. 3, 1986, p. 45-53.

Research output: Contribution to journalArticle

@article{9ba04c45b636428f9d7e8e67e0211cf8,
title = "Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer",
abstract = "The discovery that etopside is one of the most active drugs in small-cell lung cancer (SCLC) led to its incorporation into a number of first-line combination chemotherapy regimens. The cyclophosphamide/ doxorubicin/etoposide (CAE) regimen was shown to be as active or more active than other standard regimens in nonrandomized studies. In a randomized study presented in this report, the CAE regimen was significantly superior to the cyclophosphamide/doxorubicin/vincristine (CAV) regimen for response duration and survival in extensive-stage patients. In limited-stage patients the results were slightly better with CAE. In addition, CAE lacked the neurotoxicity of CAV.",
author = "Bunn, {Paul A.} and Greco, {F. Anthony} and Lawrence Einhorn",
year = "1986",
language = "English",
volume = "13",
pages = "45--53",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "3 SUPPL. 3",

}

TY - JOUR

T1 - Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer

AU - Bunn, Paul A.

AU - Greco, F. Anthony

AU - Einhorn, Lawrence

PY - 1986

Y1 - 1986

N2 - The discovery that etopside is one of the most active drugs in small-cell lung cancer (SCLC) led to its incorporation into a number of first-line combination chemotherapy regimens. The cyclophosphamide/ doxorubicin/etoposide (CAE) regimen was shown to be as active or more active than other standard regimens in nonrandomized studies. In a randomized study presented in this report, the CAE regimen was significantly superior to the cyclophosphamide/doxorubicin/vincristine (CAV) regimen for response duration and survival in extensive-stage patients. In limited-stage patients the results were slightly better with CAE. In addition, CAE lacked the neurotoxicity of CAV.

AB - The discovery that etopside is one of the most active drugs in small-cell lung cancer (SCLC) led to its incorporation into a number of first-line combination chemotherapy regimens. The cyclophosphamide/ doxorubicin/etoposide (CAE) regimen was shown to be as active or more active than other standard regimens in nonrandomized studies. In a randomized study presented in this report, the CAE regimen was significantly superior to the cyclophosphamide/doxorubicin/vincristine (CAV) regimen for response duration and survival in extensive-stage patients. In limited-stage patients the results were slightly better with CAE. In addition, CAE lacked the neurotoxicity of CAV.

UR - http://www.scopus.com/inward/record.url?scp=0022996009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022996009&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 45

EP - 53

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 3 SUPPL. 3

ER -